Antiplatelet Therapy for STEMI – Short vs. Long Duration: The Case for Ticagrelor - David Cohen, MD, FSCAI

Target Audience

• Interventional Cardiologists
• Interventional Radiologists
• Vascular Surgeons
• Interventional Fellows

Supported by educational grants from The Medicines Company, AstraZeneca, Medicure, Inc., Boehringer Ingelheim Pharmaceuticals, Inc.

Session Name: Optimization of Anticoagulation for STEMI Therapy

Track: CRT 2016 Endovascular

Learning Objectives

Update in advances in endovascular procedures

Other Components in this Moment